GLP-1 is a medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) agonists
Darbinyan, V., et al
Think of it less as a messenger and more as a foreman on a construction site, directing the local cellular machinery to patch up damage, reinforce structures, and protect against further injury
CAS No.: 2381089-83-2 Retatrutide Chemical Structure Molecular formula:C 221 H 342 N 46 O 68 Molecular weight: 4731.33 Patent period: Compound: 2026 Composition: 2029 Dositive specifications: Injection (type II diabetes, OZEMPIC): Oral tablets: Injection : Products are for laboratory research use only
Preliminary trial results further highlight substantial improvements in cardiovascular markers among patients treated with Retatrutide, including reduced systemic inflammation markers (like CRP), lowered lipid profiles, and enhanced cardiac efficiency
Retatrutide is different from Semaglutide and Tirzepatide as in addition to GLP-1 and GIP receptors, it also works on the glucagon receptor